Advertisement
Advertisement
IKT
Inhibikase Therapeutics, Inc. Common Stock
2.06
USDSponsored
+0.07
+3.52%
May 08, 15:58 UTC -4
Closed
After-Market
2.06
0.00
+0.24%
IKT Earnings Reports
Positive Surprise Ratio
IKT beat 10 of 19 last estimates.
53%
Next Report
Tomorrow
Date of Next Report
May 12, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.10
Implied change from Q4 25 (Revenue/ EPS)
--
/+11.11%
Implied change from Q1 25 (Revenue/ EPS)
--
/-41.18%
Inhibikase Therapeutics, Inc. Common Stock earnings per share and revenue
On Mar 26, 2026, IKT reported earnings of -0.09 USD per share (EPS) for Q4 25, beating the estimate of -0.10 USD, resulting in a 13.63% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of -0.10 USD, with revenue projected to reach -- USD, implying an increase of 11.11% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.37
Surprise
-9.82%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
4D Molecular Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.01
Actual
-$1.01
Surprise
+0.21%
Akebia Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-4.90%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.37
Surprise
-17.01%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
Nektar Therapeutics
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.62
Actual
-$1.82
Surprise
-11.88%
Definium Therapeutics, Inc. Common Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.71
Surprise
-41.43%
FAQ
What were Inhibikase Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Inhibikase Therapeutics, Inc. Common Stock reported EPS of -$0.09, beating estimates by 13.63%, and revenue of $0.00, 0% as expectations.
How did the market react to Inhibikase Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved -- 0%, changed from $1.63 before the earnings release to $1.63 the day after.
When is Inhibikase Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 12, 2026.
What are the forecasts for Inhibikase Therapeutics, Inc. Common Stock's next earnings report?
Based on 4
analysts, Inhibikase Therapeutics, Inc. Common Stock is expected to report EPS of -$0.10 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement